Despite the tremendous progress in the clinical management of autoimmune diseases,
many patients do not respond to the currently used treatments. Autoreactive B cells play a …

The treat-to-target (T2T) concept has improved outcomes for patients with diabetes,
hypertension and rheumatoid arthritis. This therapeutic strategy involves choosing a well …

Background Treatment for autoimmune diseases such as systemic lupus erythematosus
(SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term …

Systemic lupus erythematosus (SLE) is a life-threatening autoimmune disease characterized
by adaptive immune system activation, formation of double-stranded DNA autoantibodies …

Objectives To update the EULAR recommendations for the management of systemic lupus
erythematosus (SLE) based on emerging new evidence. Methods An international Task …

Introduction Consensus definitions for clinical remission and super-response were recently
established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed …

Objectives To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and
polymyalgia rheumatica (PMR). Methods A systematic literature review was conducted to …

Despite the continuing development of immunomodulatory agents and supportive care, the
prognosis associated with lupus nephritis (LN) has not improved substantially in the past …

Systemic lupus erythematosus (SLE) is an autoimmune disease that has diverse clinical
manifestations, ranging from restricted cutaneous involvement to life-threatening systemic …

Systemic lupus erythematosus (SLE) is a chronic multisystem auto-immune disease with
extremely varied clinical manifestations and a complex pathogenesis. New insights in SLE …